Structure Therapeutics (GPCR) Share-based Compensation (2022 - 2026)
Quarterly Share-based Compensation rose 96.67% to $11.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $27.8 million through Mar 2026, up 470.43% year-over-year, with the annual reading at $29.0 million for FY2025, 1605.35% up from the prior year.
Structure Therapeutics' Share-based Compensation history spans 5 years, with the latest figure at $11.6 million for Q1 2026.
- Share-based Compensation came in at $11.6 million for Q1 2026, up from $8.1 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $11.6 million in Q1 2026 to a low of -$11.3 million in Q4 2024.
- The 5-year median for Share-based Compensation is $2.1 million (2023), against an average of $2.7 million.
- Year-over-year, Share-based Compensation skyrocketed 308.55% in 2023 and then crashed 636.84% in 2024.
- Structure Therapeutics' Share-based Compensation stood at $623000.0 in 2022, then surged by 236.76% to $2.1 million in 2023, then plummeted by 636.84% to -$11.3 million in 2024, then soared by 171.64% to $8.1 million in 2025, then skyrocketed by 44.24% to $11.6 million in 2026.
- Per Business Quant, the three most recent readings for GPCR's Share-based Compensation are $11.6 million (Q1 2026), $8.1 million (Q4 2025), and $7.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 257.40 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Structure Therapeutics | 8.43 Bn | 8.43 Bn | - | 11.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.64 Mn |
| Mar 31, 2026 | 11.64 Mn |
| Dec 31, 2025 | 8.07 Mn |
| Dec 31, 2025 | 8.07 Mn |
| Sep 30, 2025 | 7.50 Mn |
| Sep 30, 2025 | 7.50 Mn |
| Jun 30, 2025 | 600,000.00 |
| Jun 30, 2025 | 600,000.00 |
| Mar 31, 2025 | 5.92 Mn |
| Mar 31, 2025 | 5.92 Mn |
| Dec 31, 2024 | -11.26 Mn |
| Dec 31, 2024 | -11.26 Mn |
| Sep 30, 2024 | 6.02 Mn |
| Sep 30, 2024 | 6.02 Mn |
| Jun 30, 2024 | 4.20 Mn |
| Jun 30, 2024 | 4.20 Mn |
| Mar 31, 2024 | 2.74 Mn |
| Mar 31, 2024 | 2.74 Mn |
| Dec 31, 2023 | 2.10 Mn |
| Dec 31, 2023 | 2.10 Mn |
| Sep 30, 2023 | 1.86 Mn |
| Sep 30, 2023 | 1.86 Mn |
| Jun 30, 2023 | 1.70 Mn |
| Jun 30, 2023 | 1.70 Mn |
| Mar 31, 2023 | 2.53 Mn |
| Mar 31, 2023 | 2.53 Mn |
| Dec 31, 2022 | 623,000.00 |
| Dec 31, 2022 | 623,000.00 |
| Sep 30, 2022 | 628,000.00 |
| Sep 30, 2022 | 628,000.00 |
| Jun 30, 2022 | 643,000.00 |
| Jun 30, 2022 | 643,000.00 |
| Mar 31, 2022 | 620,000.00 |
| Mar 31, 2022 | 620,000.00 |